| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.004 |
| mRNA | Panobinostat | FIMM | pan-cancer | AAC | -0.32 | 0.004 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.099 | 0.004 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.099 | 0.004 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.006 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.02 |